See more : EYEFI Group Technologies Inc. (EGTTF) Income Statement Analysis – Financial Results
Complete financial analysis of Cue Biopharma, Inc. (CUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cue Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fuel Tech, Inc. (FTEK) Income Statement Analysis – Financial Results
- Pacton Gold Inc. (PACXF) Income Statement Analysis – Financial Results
- Algonquin Power & Utilities Corp. (AQN.TO) Income Statement Analysis – Financial Results
- LB Group Co., Ltd. (002601.SZ) Income Statement Analysis – Financial Results
- FTAC Parnassus Acquisition Corp. (FTPA) Income Statement Analysis – Financial Results
Cue Biopharma, Inc. (CUE)
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.10M | 1.81M | -1.78M | 33.55M | 27.49M | 28.54M | 419.57K | 202.09K | 44.82K |
| Gross Profit | -32.61M | -560.83K | 16.72M | -30.39M | -24.03M | -27.40M | -419.57K | -202.09K | -44.82K |
| Gross Profit Ratio | -593.93% | -45.04% | 111.90% | -963.48% | -694.90% | -2,398.16% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.80M | 38.58M | 41.35M | 33.55M | 27.49M | 28.54M | 18.90M | 5.69M | 1.50M |
| General & Administrative | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Other Expenses | -37.94M | 0.00 | 0.00 | 0.00 | 64.00K | 165.34K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.54M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Cost & Expenses | 57.64M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Interest Income | 2.66M | 928.24K | 45.90K | 463.91K | 419.00K | 376.01K | 35.00 | 52.00 | 0.00 |
| Interest Expense | 1.25M | 713.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.44M | 1.81M | -1.78M | 1.06M | 5.35M | 760.01K | 419.57K | 202.09K | 44.82K |
| EBITDA | -46.05M | -50.49M | -45.44M | -43.99M | -35.96M | -37.94M | -22.81M | -7.46M | -1.88M |
| EBITDA Ratio | -838.83% | -4,076.94% | -292.56% | -1,394.44% | -1,063.30% | -3,320.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -52.15M | -53.22M | -43.71M | -45.04M | -36.77M | -38.70M | -23.23M | -7.66M | -1.93M |
| Operating Income Ratio | -949.89% | -4,274.31% | -292.56% | -1,427.96% | -1,063.30% | -3,386.71% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 215.00K | 45.90K | 463.91K | 482.79K | 541.35K | 35.00 | 52.00 | 0.00 |
| Income Before Tax | -50.73M | -53.01M | -43.67M | -44.58M | -36.29M | -38.16M | -23.23M | -7.66M | -1.93M |
| Income Before Tax Ratio | -924.10% | -4,257.09% | -292.25% | -1,413.26% | -1,049.33% | -3,339.33% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -214.43K | 495.00K | 206.25K | 412.00K | 825.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -50.73M | -52.80M | -44.16M | -44.78M | -36.70M | -38.98M | -23.23M | -7.66M | -1.93M |
| Net Income Ratio | -924.10% | -4,239.87% | -295.56% | -1,419.79% | -1,061.25% | -3,411.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| EPS Diluted | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| Weighted Avg Shares Out | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
| Weighted Avg Shares Out (Dil) | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Source: https://incomestatements.info
Category: Stock Reports